SFM
JAZZ icon

Signet Financial Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Signet Financial Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-500
Closed -$8K – 1009
2018
Q2 		$8K Buy
+500
New +$81.7K ﹤0.01% 651

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Signet Financial Management's JAZZ Position: Q2 2024 in Review

Signet Financial Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 13,380 shares — an estimated $1.61M sold.

Signet Financial Management first reported a position in JAZZ in Q1 2018 and held it in 25 quarters. The position peaked at $4.98M in Q2 2018. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Signet Financial Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Signet Financial Management sold 13,380 Jazz Pharmaceuticals shares in Q2 2024, an estimated $1.61M.
  • Signet Financial Management first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 25 quarters.
  • Signet Financial Management's Jazz Pharmaceuticals position peaked at $4.98M in Q2 2018.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Signet Financial Management's 13F filing for Q2 2024, filed 2 Aug 2024.